|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Expert Review of Gastroenterology & Hepatology
Volume 10, Issue 2, 2016
An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults
Hye Won Lee ab, Jun Yong Park abc & Sang Hoon Ahn abcd*
pages 177-186
Publishing models and article dates explained
Received: 20 Sep 2015
Accepted: 25 Nov 2015
Accepted author version posted online: 26 Nov 2015
Published online: 08 Jan 2016
ABSTRACT
Entecavir is a nucleoside analogue of 2ʹ-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus. Entecavir is recommended as a first-line monotherapy option for nucleos(t)ide-naïve patients with HBeAg-positive or -negative chronic hepatitis B infection. Entecavir has a three-step mechanism of action: It maintains viral suppression with a greater than 90% chance of undetectable hepatitis B virus DNA during continuous therapy, improves liver histology, and reduces the risk of liver failure or hepatocellular carcinoma development. The safety profile of long-term entecavir therapy is favorable; however, its optimal treatment duration is unknown. Entecavir monotherapy is not a rescue option for patients with lamivudine/adefovir resistance or baseline lamivudine-resistant mutants; rather, combination treatment is recommended for patients with lamivudine/adefovir resistance.
|
|
发表于 2016-2-3 21:51